BTIG reiterates Buy rating on Acumen Pharmaceuticals; $8 target
BTIG reiterated a Buy rating on Acumen Pharmaceuticals and set a $8.00 price target, implying 176.8% upside from the Sep 15 close of $2.89.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.